MEB-1170 is an oral analgesic to solve the opiod crisis

indication for meb-1170

  • Replacement of Schedule II opioids in pain management (e.g. Oxycodone)
  • Treat moderate-to-severe pain
  • Estimated once a day
  • Home-use pain management after surgery and management of chronic pain conditions

MEB-1170 Treats pain without opioid adverse effects


Active in 3 Rodent Pain Models

No Respiratory Depression

    • Oral with long half-life
    • As efficacious as morphine
    • Confirmed in 3 in vivo pain models (Formalin Induced Pain, Post Incisional Pain, Tail Flick)
    • Acute and chronic oral dosing
    • Normal pO2, pCO2, pH
    • Normal respiratory drive (Respiratory Rate, Minute Volume, Tidal Volume)

Devoid of Other Serious Issues Seen in Marketed Opioids

    • Does not produce tolerance to analgesia
    • Does not cause constipation
    • Does not cause sedation
    • No toxicity seen in observational reads

MEB-1170 Shows no abuse potential in FDA required preclinical models for CNS Drugs


No Drug Seeking Behavior

No Self-Administration

Minimal Withdrawal

Drug Discrimination

MEB-1170 has the potential to prevent and to treat opioid abuse in patients undergoing pain therapy

Rats abusing Oxycodone do not abuse MEB-1170

Rats using MEB-1170 do not abuse Oxycodone